Key Drivers
- Liquidity cushion
- Operating losses
- Cash burn
AIAI Summary
SPRY is no longer a simple launch upside story; it is now a reimbursement-execution bet, with solid liquidity and early Neffy demand offset by formulary misses that threaten revenue scaling, keep losses/cash burn elevated, and can pressure the equity if payer wins don't accelerate soon.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity cushion
- •Operating losses
- •Cash burn
SPRY has strong near-term liquidity and cash reserves, but persistent operating losses, heavy free-cash-flow burn, and declining equity make the stock financially risky.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Support holding
- •Reclaim needed
Over the last month, SPRY rallied from the low-$8s to $10.54 before a failed breakout on 6/25 sent it back to support around $7.94–$8.02, leaving the trend mixed until it can reclaim $9.65–$9.98.
Sharp rejection above $10 on 2026-06-25 quickly sent price back into the low-$8s
Sentiment & News
Key News Insights:
- •Formulary miss
- •Share slump
- •Legal probes
ARS Pharmaceuticals suffered a sharp commercial setback after CVS Caremark declined to add Neffy to its formulary, triggering a >23% share drop and prompting investor litigation scrutiny despite management reaffirming 2027 cash-flow breakeven guidance.
The missed payer win weakens near-term Neffy adoption prospects and may keep ARS shares under pressure amid rising litigation risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings